Dear TrialNet Family,
TrialNet has been investigating the role of oral insulin in T1D for nearly 20 years. Most recently, we completed the Oral Insulin Prevention Study—the largest study of its kind, conducted over 10 years with 560 relatives of people with T1D.
As we announce the study findings, I want to take this opportunity to recognize this incredible accomplishment and thank everyone involved.
First and foremost, on behalf of everyone in TrialNet and type 1 diabetes researchers around the world, I want to say a heartfelt thank you to the families who participated in the study. Please know you have and will continue to make a difference in our mission to find a way to delay, prevent and ultimately cure type 1 diabetes.
To the TrialNet nurses and healthcare providers who took such great care of participating families and upheld the highest research standards, we greatly appreciate your hard work and dedication.
To fellow researchers and scientists in and out of TrialNet, let this be a reminder that our time and efforts are impactful.
We would also like to thank the National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the American Diabetes Association and JDRF for their continued support. We also thank Congress for funding the Special Diabetes Program, an important program that provides critical funding for NIH T1D research.
I look forward to sharing more accomplishments as we work toward our ultimate goal: a future without T1D.
Sincerely,Carla Greenbaum, M.D.
Diabetes Clinical Research Program Director, Benaroya Research Institute at Virginia Mason